Decitabine combined with conventional chemotherapy improves outcome in pediatric AML: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023368

Enrollment

Unknown

Registered

2019-05-24

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Decitabine Group:Decitabine and conventional chemotherapy

Control Group:conventional chemotherapy

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients must be 1 -18 years of age at the time of diagnosis; 2. Patients must have a diagnosis of AML ( WHO criteria); 3. relapse or de novo AML.

Exclusion criteria

Exclusion criteria: 1. Evidence of active, uncontrolled infection; 2. Known allergy to any of the agents or their ingredients used in this study.

Design outcomes

Primary

Measure	Time frame
DNA methylation Status;	—

Secondary

Measure	Time frame
Overall Survival Rate;Even Free Survival Rate;	—

Countries

China

Contacts

Public ContactChun Chen

The Seventh Affiliated Hospital, Sun Yat-sen University

chenchun69@126.com+86 13719003063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026